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Spontaneous proteolysis of influenza virus M1 protein during crystallisation has defined an N-terminal domain of amino
acids 1–164. Full-length M1, the N-terminal domain, and the C-terminal part of M1 (residues 165–252) were produced in
Escherichia coli. In vitro tests showed that only full-length M1 and its N-terminal domain bind to negatively charged liposomes
and that only full-length M1 and its C-terminal part bind to RNP. However, only full-length M1 had transcription inhibition
activity. Several independent experimental approaches indicate that in vitro transcription inhibition occurs through polymeri-
sation/aggregation of M1 onto RNP, or of M1 onto M1 already bound to RNP, rather than by binding to a specific active site
on the nucleoprotein or the polymerase. The structure/function of influenza virus M1 will be compared with that of the Ebola
virus matrix protein, VP40. © 2001 Academic Press
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bINTRODUCTION
Influenza virus is a segmented negative-strand RNA
virus. The virus has a transport component and a repli-
cation component. The transport component consists of
a lipid membrane with two external, membrane-an-
chored glycoproteins (haemagglutinin and neuramini-
dase) plus a membrane channel (M2), which are re-
quired for cell entry and release of newly formed virus
particles. The replication component consists of the
eight viral RNA segments, each encapsidated by the
nucleoprotein and each individually containing a poly-
merase complex (for reviews, see Lamb and Krug, 1996;
Ruigrok, 1998). In the virus particle, these two compo-
nents are linked together by the M1 protein (Oxford and
Hockley, 1987; Zhang et al., 2000a) that plays an impor-
ant role during the viral budding process. M1 forms a
ayer just underneath the membrane (Nermut, 1972;
chulze, 1972; Ruigrok et al., 1989). Recent electron mi-
crographs of negatively stained virus suggest that M1 is
a 6-nm-long, thin rod that touches the membrane with
one of its ends (Ruigrok et al., 2000a).
In vitro interaction of M1 with RNP has been shown by
an inhibitory action of M1 when added to actively tran-
scribing RNPs (Ye et al., 1987, 1989; Watanabe et al.,
1996; Elster et al., 1997) and by M1–RNP co-sedimenta-
tion studies (Watanabe et al., 1996; Ye et al., 1999).
Interaction of M1 with lipid membranes has been studied
inside the virus by hydrophobic photolabelling (Grego-
riades and Frangione, 1981; Ruigrok et al., 2000a), by in
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102vitro M1–liposome interactions (Bucher et al., 1980; Ye et
al., 1987; Ruigrok et al., 2000a) and by studying the fate of
M1 expressed in cells, either by M1-plasmid DNA trans-
fection or by influenza virus infection (Enami and Enami,
1996; Kretzschmar et al., 1996; Zhang and Lamb, 1996). It
is generally assumed that the M1–lipid membrane inter-
action is hydrophobic. However, we recently showed that
there is an important electrostatic component contribut-
ing to the membrane-binding activity of M1 (Ruigrok et
al., 2000a); in vitro, M1 binds to negatively charged lipo-
somes, and this binding is prevented at high salt and at
high pH.
The N-terminal 164 residues of M1 have been crystal-
lised (Sha and Luo, 1997). Although these authors had
set out to crystallise intact M1 isolated from virus, the
crystals contained only the N-terminal fragment. We have
done a similar crystallisation experiment with intact re-
combinant M1 protein produced in E. coli and have
obtained crystals containing the same N-terminal frag-
ment (Arzt et al., 2001). This suggests that this N-terminal
fragment may form an independent domain and that the
cleavage site must be exposed to contaminating pro-
teases (present in the virus preparation and in the re-
combinant preparation from E. coli). When M1 is solubi-
lized from virus or when it is purified as a recombinant
protein from E. coli, the protein in solution is significantly
longer than when observed by electron microscopy in-
side the virus, and the N-terminal domain appears flex-
ibly linked to the C-terminal domain that has 40% a-he-
ical content (Arzt et al., 2001).
In the present paper, we have tested full-length recom-
inant M1(1–252), the N-terminal domain M1(1–164), andhe remaining C-terminal domain M1(165–252) with re-
pect to their binding to negatively charged liposomes
103RNP AND MEMBRANE BINDING DOMAINS OF INFLUENZA VIRUS M1and to RNPs and their ability to inhibit transcription. We
show that only full-length M1 and M1(1–164) bind to
liposomes and that full-length M1 and M1(165–252) bind
to RNP. However, only full-length M1 was active in tran-
scription inhibition.
RESULTS AND DISCUSSION
Full-length M1(1–252), the N-terminal domain M1(1–
164), and the remaining C-terminal part M1(165–252)
were expressed in E. coli and purified: the full-length
protein and the N-terminal domain without tags and
C-terminal M1(165–252) with an N-terminal His-tag. An
SDS–PAGE gel is shown in Fig. 1 with the two peak
fractions of the last purification step of each of the three
polypeptides.
FIG. 1. PAGE (15%) of purified M1 protein and its truncated forms.
Lanes 1 and 2: two peak fractions eluted from the last column of
purified M1(165–252); lanes 3 and 4: two peak fractions of the last
purification step of M1(1–164); lanes 5 and 6: two peak fractions of the
last purification step of full-length M1 protein (1–252). The gel was
stained with Coomassie blue.
FIG. 2. Interaction of M1 with liposomes. M1 and its two fragments
were incubated with negatively charged liposomes and floated in a
sucrose step gradient. The figure shows a SDS–PAGE of the harvested
gradient fractions. Two panels are shown for each protein, one with
and one without liposomes as indicated.Figure 2 shows the results of the liposome binding
experiments. Full-length M1 and M1(1–164) float with
negatively charged liposomes on a sucrose gradient, but
M1(165–252) does not float. This strongly suggests that
the N-terminal domain of M1 is sufficient for membrane
interaction. The results on the interaction with RNPs are
the opposite, shown in Fig. 3A. Full-length M1 and the
C-terminal M1(165–252) bind to RNP and co-sediment
through an 18% glycerol cushion. In contrast, the N-
terminal domain does not bind to RNP. Co-sedimentation
experiments with RNP that had the polymerase complex
removed gave the same results (not shown). M1 and
M1(165–252) also co-sedimented with purified viral nu-
cleoprotein alone, that is, without the polymerase and
without RNA (Fig. 3B). Nucleoprotein alone can polymer-
ise into structures that are very similar to intact RNPs
and that are large enough to sediment through 18%
glycerol (Ruigrok and Baudin, 1995).
These results suggest a likely orientation for the 6-nm
M1 rod in the influenza virus particle: the end of the rod
touching the membrane could be the N-terminal domain
and the opposite end of the rod could be the C-terminal
end of the protein contacting the RNPs. The data are also
in agreement with the hypothesis put forward in Ruigrok
FIG. 3. Binding of M1 to RNP and to purified nucleoprotein free of
RNA. M1 protein and its truncated fragments were mixed with RNPs (A:
RNP) or with purified, RNA-free nucleoprotein (B: NP), and the RNP–M1
complexes were sedimented through a 18% glycerol cushion. The
pellets were resuspended and analysed on 15% SDS–PAGE. Ct, control,
pellet of M1 (or its fragments) without RNP or NP. Conditions 1 and 2:
increasing amounts of M1 with constant amount of RNP (NP) as
indicated under Materials and Methods. The gels were stained with
Coomassie blue.et al. (2000a) suggesting that a positively charged patch,
as seen in the atomic structure of the N-terminal domain
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104 BAUDIN ET AL.of M1 (Sha and Luo, 1997; Arzt et al., 2001), might be
nvolved in membrane binding, similar to the electro-
tatic interactions proposed for the membrane binding of
etroviral matrix proteins (Conte and Matthews, 1998).
ur present results show that this positive patch, which
as identified as the nuclear localisation sequence (Ye
t al., 1995) and which is responsible for in vitro binding
to naked RNA (Watanabe et al., 1996; Elster et al., 1997),
oes not bind to intact viral RNP. In RNP, the vRNA is
omplexed to the viral nucleoprotein that binds to and
hields the negatively charged phosphate-sugar back-
one of the RNA (Baudin et al., 1994). Here we show that
he C-terminal end of M1 binds to the RNPs, and our
esults suggest that, under the in vitro conditions used
ere, binding is most likely to the nucleoprotein and not
o the RNA or to the polymerase.
We subsequently tested the in vitro transcription inhi-
ition activities of the three polypeptides. Figure 4 shows
hat only full-length M1 inhibits transcription in vitro, the
wo smaller fragments are inactive. The strongest inhi-
ition obtained was ;80% at an input ratio of 150 mole-
ules M1 per RNP (or 2 M1 per nucleoprotein molecule).
t is not surprising that M1(1–164) does not inhibit since
t does not bind to RNP. However, the C-terminal frag-
ent seems to bind with a higher stoichiometry to RNP
han M1 (Fig. 3A) but does not inhibit transcription. We
lso added equal amounts of the N-terminal plus the
-terminal fragments to RNPs but still found no inhibition
data not shown).
In Elster et al. (1997), a mutant M1 protein was de-
cribed that had all positively charged amino acids of the
LS sequence (between residues 95 and 105) changed
o alanine. This NLS-mutant M1 no longer binds to naked
FIG. 4. Transcription inhibition experiment using viral RNP plus M1 or
its two fragments. In vitro transcription experiments using purified RNP
were performed as described under Materials and Methods. Transcrip-
tion in the absence of M1 was put at 100% and the inhibition of
transcription was measured in the presence of varying amounts of M1
or its fragments as indicated below the figure.NA (Elster et al., 1997) but still shows transcription
nhibition activity, albeit to a lower extent, with a maxi-um inhibition of 50% at 350 molecules of M1 per RNP
Fig. 5A, see also Elster et al., 1997). We tested binding of
his NLS-mutant M1 to RNP and found that it did indeed
ind (Fig. 5B), which was expected since it has the same
-terminal sequence as wt M1. Because the RNP-bind-
ng C-terminal parts of wt and NLS-mutant M1 proteins
re the same, some other mechanism than the initial
ffinity of the two M1 proteins for RNP must be the cause
f the lower efficiency in transcription inhibition.
M1 is a protein with a strong tendency to aggregate or
olymerise depending on in vitro conditions such as
uffer composition and temperature (Ruigrok et al.,
000a). M1 preparations normally contain small aggre-
ates, therefore all M1 preparations were centrifuged to
emove these preexisting aggregates for the experi-
ents described above. The NLS-mutant M1 protein has
much lesser tendency to polymerise than wt M1. To
emonstrate this, we tested the solubility of the preex-
sting aggregates of wt and NLS-mutant M1 proteins as
function of salt concentration (Fig. 5C). Whereas wt M1
FIG. 5. Transcription inhibition, RNP binding and salt-dependent
solubility of wild-type M1 and NLS-mutant M1. (A) Transcription inhibi-
tion as described for Fig. 4 using wt and NLS-mutant M1. (B) Binding of
NLS-mutant to RNPs as described for Fig. 3A. (C) Wild-type and NLS-
mutant M1 preparations were incubated under different salt conditions
and then spun in an airfuge. The pellets were analysed on 15% SDS–
PAGE which were stained with Coomassie blue.
o ough a
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NaCl, preexisting aggregates of NLS-mutant M1 are sol-
ubilized at much lower salt concentrations, between 10
and 50 mM NaCl. This may be due to the fact that the
N-terminal part of the wt protein has a clearly defined
negatively charged face and an opposite, positively
charged face. Packing of these two faces onto each
other forms one of the crystal packing interfaces in the
pH 7 crystals of M1(1–164) (Arzt et al., 2001). Salt is likely
to have an influence on such electrostatic interactions.
FIG. 6. Electron micrographs of negatively stained, in vitro formed RN
f M1 per RNP). (C) Same sample as in (B) but after sedimentation thr
1(165–252) per RNP] without centrifugation over a glycerol cushion. T
00 nm.The NLS strongly contributes to the positive charges,
and mutation of the NLS will probably lead to lowerelectrostatic interactions between M1 molecules. This
difference in solubility correlates with and may be the
cause of the difference in transcription inhibition activi-
ties of wt and NLS-mutant M1 proteins. Transcription
inhibition may be due to or enhanced by polymerisation
of M1 onto M1 that is already bound to RNP.
We studied the M1–RNP complexes with electron mi-
croscopy both before and after sedimentation through
18% glycerol under the conditions of maximum transcrip-
tion inhibition as described for Fig. 3. Figure 6A shows
omplexes. (A) RNP without M1. (B) RNP with added M1 (150 molecules
n 18% glycerol cushion. (D) RNP with M1(165–252) [300 molecules of
wheads in (B) and (C) indicate RNP–M1 complexes. The bar indicatesP-M1 ccontrol RNPs purified from disrupted virus as used for
the transcription inhibition experiments. Figure 6B shows
106 BAUDIN ET AL.the same RNPs mixed with wt M1(1–252). The arrow-
heads indicate the large, aggregated RNP-M1 com-
plexes, whereas the smaller flexible filaments in the
background are homo-polymers of M1 (Ruigrok et al.,
2000a). Figure 6C shows the same preparation after
centrifugation through the glycerol cushion. Lumps of M1
are still attached to the RNPs, which are sometimes
deformed and hardly recognisable as RNPs. The main
reason that we think that these structures are indeed
RNP–M1 complexes is that they are absent in control
experiments with M1 protein alone. Figure 6D shows
RNPs incubated with M1(165–252) without sedimenta-
tion through glycerol. Although the background is full of
small material and although the fine details of the RNPs
are obscured by the presence of the bound M1(165–252),
there are no aggregates of the M1 fragment, neither in
the background nor attached to the RNPs. The general
shape of the RNPs does not seem to be perturbed. These
pictures suggest that large-scale polymerisation/aggre-
gation of M1 onto the RNPs is the cause of transcription
inhibition rather than binding of M1 to specific sites on
the RNP, such as the active site of one of the polymerase
subunits. This interpretation would agree with the finding
that maximum transcription inhibition occurs only at high
M1:RNP input ratios (as shown here and elsewhere;
Watanabe et al., 1996; Elster et al., 1997). Watanabe et al.
(1996) have described co-operative binding of M1 to
M1–RNA complexes efficiently competing with binding of
M1 to naked RNA, and Ye et al. (1999) reported that the
salt concentration has a large effect on the in vitro
association of M1 to RNP.
These in vitro results of binding of M1 to RNP and
purified NP are different from the in vivo results by Zhao
et al. (1998), who have shown that M1 and NP when
co-expressed in BHK-21 cells form homo- but not hetero-
oligomeric complexes. It would seem likely that in an
actual influenza virus infection, the M1 protein binds
neither to the cell membrane nor to cytoplasmic RNPs
until the moment of budding. Even though the presence
of M1 in the nucleus of the infected cell is needed for
efficient nuclear export of RNP (Martin and Helenius,
1991, Bui et al., 2000), there is no proof that significant
amounts of M1 are actually accompanying RNP out of
the nucleus (Bui et al., 2000; Zhirnov and Klenk, 1997).
The recombinant M1 protein that we have used in the
present set of experiments fully resembles M1 isolated
from virus in secondary structure, RNA, and RNP binding
and transcription inhibition (Elster et al., 1997). The only
difference between viral and recombinant M1 proteins is
that a small proportion of the viral M1 protein has a zinc
ion bound (Elster et al., 1994), whereas the recombinant
protein does not contain any zinc (within the detection
limits; D. Waku and R. Ruigrok, unpublished results). This
M1 protein has affinity for negatively charged mem-
branes, for RNP, and for itself (self-association). Figure 7
shows a comparison of the domain structure and activ-ities of the influenza M1 protein with those of the Ebola
virus matrix protein, VP40. VP40 is expressed and iso-
lated as a soluble, monomeric protein in which the N-
and C-terminal domains are loosely associated (Dessen
et al., 2000). When this protein is destabilised by low
concentrations of urea and also when the protein is
incubated with negatively charged liposomes, the two
domains separate and remain flexibly attached. This
separation allows the N-terminal domains to oligomerise
and the C-terminal domains to bind to the liposomes
(Ruigrok et al., 2000b; Scianimanico et al., 2000). The
crystal structure of the oligomeric form (a hexameric
ring) has not been determined yet, and we do not know
the protein interfaces in the hexamer. However, it is
conceivable that the association of the N- and C-terminal
domains in the soluble, monomeric form hides the oli-
gomerisation and lipid binding interfaces that are ex-
posed in the “activated” form of VP40.
The structures of VP40 and the N-terminal domain of M1
are totally different. However, from a functional point of
view, the proteins are likely to perform the same roles in the
virus budding processes. The form of the influenza M1
protein that we have worked with in the present publication
is likely to correspond to the activated form of VP40. Al-
though nobody has yet shown the existence of a soluble,
FIG. 7. Comparison of the Ebola virus and influenza virus matrix
proteins. Ebola virus VP40 is a soluble monomer that forms oligomers
when the monomer is destabilised by urea or in the presence of
negatively charged liposomes. In the monomers, the N-terminal do-
main is associated with the C-terminal domain, and in the oligomers,
the two domains are separated and flexibly linked (Scianimanico et al.,
2000). The N-terminal domain is involved in oligomerisation and the
C-terminal domain binds to the liposomes (Ruigrok et al., 2000b). The
N-terminal domain may also be involved in nucleocapsid binding al-
though this has not yet been shown. The influenza virus M1 protein has
only been isolated in a form where the N-terminal domain is separated
from and flexibly linked to the C-terminal domain. The activities of the
two domains are described in the present paper. As shown in the
present paper, both domains are needed for efficient polymerisation.monomeric, and functionally “inactive” form of M1, in anal-
ogy with VP40 such a form of M1 may exist. In this inactive
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107RNP AND MEMBRANE BINDING DOMAINS OF INFLUENZA VIRUS M1conformation, the binding sites for membranes, RNP, and
other M1 molecules could be masked. Binding of the hy-
pothetically inactive form of M1 to ordered lipid rafts with
embedded cytoplasmic tails of the glycoproteins (Zhang et
al., 2000b) could induce a conformational change that ex-
poses the interfaces for RNP binding and for M1 self-
association. The zinc binding sequence in M1 is positioned
right between the N- and C-terminal domains (Sha and Luo,
1997), and it is possible that the presence or absence of a
zinc ion in M1 has an influence on the relative orientation of
the two domains.
MATERIALS AND METHODS
Proteins
M1(1–252), M1(1–164), and M1(165–252) were pro-
duced in E. coli as described in Arzt et al. (2001). NLS-
mutant M1 protein with all positively charged amino
acids between residues 95 and 105 changed to alanines
(95-AAVALYAALAA-105, changed residues underlined)
was described in Elster et al. (1997). The construct was
subcloned into pet16b (Novagen) to remove the se-
quence coding for the poly-His tail. The new plasmid was
expressed in E. coli BL21(DE3) pLysS after induction with
0.5 mM IPTG (isopropyl thiogalactoside) at 30°C. The
bacteria were lysed by sonication, and the NLS-mutant
M1 was purified by a two-step FPLC protocol using first
an ion exchange column (SP Sepharose FF) and second
a gel-exclusion column (Superdex 75, Pharmacia). Dur-
ing purification the protein was kept at pH 5.7 in a buffer
containing 20 mM MES–KOH, 250 mM NaCl, 10 mM
MnCl2, and 10 mM b-mercaptoethanol.
Before the M1–RNP co-sedimentation, the M1-lipo-
some floatation, and the transcription inhibition experi-
ments (see below), all M1 protein preparations were
centrifuged at 20 psi in a Beckman airfuge to remove
preexisting aggregates.
Liposome preparation
Five milligrams L-a-phosphatidylcholine (25%) (Sigma),
10 mg L-a-phosphatidyl-L-serine (50%) (Sigma), 5 mg cho-
esterol (25%), and 20 mg n-octyl b-D-glucopyranoside
ere dissolved in 8 ml ethanol. The solution was then
ried down in a vacuum evaporator, and the lipid film
as resuspended in 4 ml PBS. The solution was slightly
loudy and was sonicated for 15 min on ice. N-octyl
b-D-glucopyranoside was then removed by dialysis with
a liposomat (Dianorm) for 3 h at room temperature. Li-
posomes were passed through a 0.22-mm filter, and the
quality was checked by negative staining electron mi-
croscopy, which revealed an estimated diameter size
distribution of 50–200 nm.
Membrane floatation experimentsOne hundred micrograms of protein [4 mmol for M1(1–
52) and 8 mmol for the two fragments] was incubated
mith 200 ml of liposomes (lipid concentration of 4 mg/ml)
for 1 h at 37°C. The volume was then adjusted to 1 ml in
40% sucrose in a buffer containing 20 mM Tris–HCl, pH
7, 100 mM NaCl, and 10 mM DTT. A discontinuous gra-
dient was formed with 1 ml sample in 40% sucrose at the
bottom, overlaid with 1.5 ml 35% sucrose (w/v), 1 ml 20%
sucrose (w/v), 0.75 ml 10% sucrose (w/v), and 0.75 ml 5%
sucrose (w/v) in the same buffer as indicated above.
Centrifugation was performed in a SW55 rotor at 40,000
rpm for 14 h at 12°C. Fractions collected from the gradi-
ents were analysed by SDS–PAGE and Coomassie bril-
liant blue staining. As controls, proteins without lipo-
somes were centrifuged and analysed as above.
M1–RNP binding
The isolation and purification of viral RNPs was de-
scribed in Klumpp et al. (1997). Thirty microliters RNP
(;12 mg or 3 pmol of RNP corresponding to 225 pmol of
NP bound to RNA) was incubated for 1 h at room tem-
perature with increasing amounts of full-length M1(1–
252) (condition 1: 10 mg corresponding to 370 pmol;
condition 2: 20 mg), M1(1–164) (condition 1: 10 mg corre-
ponding to 550 pmol; condition 2: 30 mg), or M1(165–
252) (condition 1: 5 mg corresponding to 380 pmol; con-
dition 2: 15 mg) in 130 ml final buffer (50 mM Tris–HCl,
pH7.5, 150 mM NaCl, and 5 mM MgCl2). The M1–RNP
ixture was put on top of a 18% glycerol cushion (420 ml
n the same buffer as above) and centrifuged for 1 h at 55
rpm in a SW55 rotor at 12°C. The controls were done
ith the M1 proteins only. The pellets were solubilized in
DS–PAGE sample buffer and directly analysed on
AGE. Similar co-sedimentation experiments were per-
ormed with RNP minus the polymerase subunits (pre-
ared according to Klumpp et al., 1997) and with purified
NP free of RNA (prepared according to Ruigrok and
Baudin, 1995).
Transcription inhibition experiments
RNP transcription inhibition assays were carried out
using a fixed amount of RNP (1.5 pmol) and increasing
amounts of M1 as indicated in Figs. 4 and 5A in 50 mM
Tris–HCl pH 7.8, 100 mM KCl, 5 mM MgCl2, 10 mM DTT,
.4 mM ApG, 1 mM ATP, 0.5 mM GTP, 0.5 mM UTP, 0.1
M CTP, and 20 mCi [a32P]UTP; total volume, 50 ml. After
incubation for 1 h at 37°C, the transcripts were precipi-
tated for 30 min on ice by addition of 12.5% TCA (final)
and 1% casamino acids (final), filtered on GF/A filters,
and then rinsed with 5 ml of 10% TCA. The filters were
dried and counted in a scintillation counter.
M1 solubility test
Wild-type and NLS-mutant M1 proteins at 50 mg/ml
ere incubated for 40 min at room temperature in a 10
M MES-KOH, pH 5.7, buffer containing 10 mM MnCl2
and various NaCl concentrations (see Fig. 5). Then the
108 BAUDIN ET AL.solution was centrifuged for 10 min in a Beckman airfuge
at 10 psi, and the pellet was taken up in Laemmli gel
buffer and analysed on SDS–PAGE. Note that in contrast
to all other experiments described above, this experi-
ment tests the presence and solubilisation of preexisting
aggregates in the M1 preparation.
Negative stain electron microscopy
M1–RNP protein complexes (0.1 mg/ml total concentra-
tion) were adsorbed to the clean side of a carbon film on
mica (mica/carbon interface), negatively stained with 1%
sodium silicotungstate, air-dried, and observed in a JEOL
1200 EX-II electron microscope under low-dose conditions.
ACKNOWLEDGMENTS
We thank Christine Alberti for doing the experiment shown in Fig. 5c and
Diane Waku for atomic absorption measurements on recombinant M1.
REFERENCES
Arzt, A., Baudin, F., Barge, A., Timmins, P., Burmeister, W. P., and
Ruigrok, R. W. H. (2001). Combined results from solution studies on
intact influenza virus M1 protein and from a new crystal form of its
N-terminal domain shows that M1 is an elongated monomer. Virol-
ogy 279, 439–446.
Baudin, F., Bach, C., Cusack, S., and Ruigrok, R. W. H. (1994). Structure
of influenza virus RNP. I. Influenza virus nucleoprotein melts second-
ary structure in panhandle RNA and exposes the bases to the
solvent. EMBO J. 13, 3158–3165.
Bucher, D. J., Kharitonenkov, I. G., Zakomirdin, J. A., Grigoriev, V. B.,
Klimenko, S. M., and Davis, J. F. (1980). Incorporation of influenza
virus M-protein into liposomes. J.Virol. 36, 586–590.
Bui, M., Wills, E. G., Helenius, A., and Whittaker, G. R. (2000). Role of the
influenza virus M1 protein in nuclear export of viral ribonucleopro-
teins. J. Virol. 74, 1781–1786.
Conte, M. R., and Matthews, S. (1998). Retroviral matrix proteins: A
structural perspective. Virology 246, 191–198.
Dessen A., Volchkov V., Dolnik O., Klenk H. D., and Weissenhorn W.
(2000). Crystal structure of the matrix protein VP40 from Ebola virus.
EMBO J. 19, 4228–4236.
Elster, C., Fourest, E., Baudin, F., Larsen, K., Cusack, S., and Ruigrok,
R. W. H. (1994). A small percentage of influenza virus M1 protein
contains zinc but zinc does not influence in vitro M1-RNA interaction.
J. Gen. Virol. 75, 37–42.
Elster, C., Larsen, K., Gagnon, J., Ruigrok, R. W. H., and Baudin, F. (1997).
Influenza virus M1 protein binds to RNA through its nuclear local-
isation signal. J. Gen. Virol. 78, 1589–1596.
Enami, M., and Enami, K. (1996). Influenza virus hemagglutinin and
neuraminidase glycoproteins stimulate the membrane association of
the matrix protein. J. Virol. 70, 6653–6657.
Gregoriades, A., and Frangione, B. (1981). Insertion of influenza M
protein into the viral lipid bilayer and localization of site of insertion.
J. Virol. 40, 323–328.
Klumpp K., Ruigrok R. W. H., and Baudin F. (1997). Roles of the influenza
virus polymerase and nucleoprotein in forming a functional RNP
structure. EMBO J. 16, 1248–1257.
Kretzschmar, E., Bui, M., and Rose, J. K. (1996). Membrane association
of influenza virus matrix protein does not require specific hydropho-
bic domains or the viral glycoproteins. Virology 220, 37–45.
Lamb, R. A., and Krug, R. M. (1996). Orthomyxoviridae: The viruses andtheir replication. In “Fields Virology,” 3rd ed. (B.N. Fields, D.M. Knipe,
P.M. Howley et al., Eds.). Lippincot-Raven Publishers, Philadelphia.
Martin, K., and Helenius, A. (1991). Nuclear transort of influenza virus
proteins: The viral matrix protein (M1) promotes export and inhibits
import. Cell 67, 117–130.
Nermut, M. V. (1972). Further investigation on the fine structure of
influenza virus. J. Gen. Virol. 17, 317–331.
Oxford, J. S., and Hockley, D. J. (1987). Orthomyxoviridae. In “Animal
Virus Structure” (M. V. Nermut and A. C. Steven, Eds.), pp. 213–232.
Elsevier, Amsterdam.
Ruigrok, R. W. H. (1998). Structure of influenza A, B, and C viruses. In
“Textbook of influenza” (K. G. Nicholson, R. G. Webster, and A. J. Hay,
Eds.), pp. 29–42. Blackwell Science Ltd., Oxford.
Ruigrok, R. W. H., and Baudin, F. (1995). Structure of Influenza virus RNP.
II. Purified, RNA-free Influenza ribonucleoprotein forms structures
that are indistinguishable from the intact viral ribonucleoprotein
particles. J. Gen. Virol. 76, 1009–1014.
Ruigrok, R. W. H., Barge, A., Durrer, P., Brunner, J., Ma, K., and Whittaker,
G. R. (2000a). Membrane interaction of influenza virus M1 protein.
Virology 267,289–298.
Ruigrok, R. W. H., Calder, L. J., and Wharton, S. A. (1989). Electron
microscopy of the influenza virus submembranal structure. Virology
173, 311–316.
Ruigrok, R. W. H., Schoehn, G., Dessen, A., Forest, E., Volchkov, V.,
Dolnik, O., Klenk, H.-D., and Weissenhorn, W. (in Press). Structural
characterization, and membrane binding properties of the matrix
protein VP40 of Ebola virus. J. Mol. Biol.
Schulze, I. T. (1972). The structure of influenza virus. II. A model based
on the morphology and composition of subviral particles. Virology 47,
181–196.
Scianimanico, S., Schoehn, G., Timmins, J., Ruigrok, R. W. H., Klenk,
H.-D., and Weissenhorn, W. (in press). Membrane association in-
duces a conformational change in the Ebola virus matrix protein.
EMBO J.
Sha, B., and Luo, M. (1997). Structure of a bifunctional membrane-RNA
binding protein, influenza virus matrix protein. Nat. Struct. Biol. 4,
239–244.
Watanabe, K., Handa, H., Mizumoto, K., and Nagata, K. (1996). Mecha-
nism for inhibition of influenza virus RNA polymerase activity by
matrix protein. J. Virol. 70, 241–247. mcYe, Z., Baylor, N. W., and
Wagner, R. R. (1989). Transription inhibition and RNA-binding do-
mains of infuenza virus matrix protein mapped with anti-idiotypic
antibodies and synthetic peptides. J. Virol. 63, 3586–3594.
Ye, Z., Liu, T., Offringa, D. P., McInnis, J., and Levandowski, R. A. (1999).
Association of influenza virus matrix protein with ribonucleoproteins.
J. Virol. 73, 7467–7473.
Ye, Z., Pal, R., Fox, J. W., and Wagner, R. R. (1987). Functional and
antigenic domains of the matrix (M1) protein of influenza A virus.
J. Virol. 61, 239–246.
Ye, Z., Robinson, D., and Wagner, R. R. (1995). Nucleus-targeting domain
of the matrix protein (M1) of influenza virus. J. Virol. 69, 1964–1970.
Zhang, J., and Lamb, R. A. (1996). Characterization of the membrane
association of the influenza virus matrix protein in living cells. Virol-
ogy 225, 255–266.
Zhang, J., Leser, G. P., Pekosz A., and Lamb, R. A. (2000a). The cyto-
plasmic tails of the influenza virus glycoproteins are required for
normal genome packing. Virology 269, 325–334.
Zhang, J., Pekosz, A., and Lamb, R. A. (2000b). Influenza virus assembly
and lipid raft microdomains: A role for the cytoplasmic tails of the
spike glycoproteins. J.Virol. 74, 4634–4644.
Zhao H, Ekstro¨m M, Garoff H. (1998). The M1 and NP proteins of
influenza A virus form homo- but not heterooligomeric complexes
when co-expressed in BHK-21 cells. J. Gen. Virol. 79,2435–2346.Zhirnov, O. P., and Klenk, H.-D. (1997). Histones as a target for influenza
virus matrix protein M1. Virology 235, 302–310.
